Parallel Advisors, LLC Akero Therapeutics, Inc. Transaction History
Parallel Advisors, LLC
- $4.87 Billion
- Q2 2025
A detailed history of Parallel Advisors, LLC transactions in Akero Therapeutics, Inc. stock. As of the latest transaction made, Parallel Advisors, LLC holds 5,166 shares of AKRO stock, worth $266,152. This represents 0.01% of its overall portfolio holdings.
Number of Shares
5,166
Previous 5,169
0.06%
Holding current value
$266,152
Previous $220,000
25.0%
% of portfolio
0.01%
Previous 0.01%
Shares
13 transactions
Others Institutions Holding AKRO
# of Institutions
271Shares Held
86MCall Options Held
1.02MPut Options Held
823K-
Rtw Investments, LP New York, NY7.42MShares$382 Million4.92% of portfolio
-
Janus Henderson Group PLC London, X07.07MShares$364 Million0.16% of portfolio
-
Wellington Management Group LLP Boston, MA5.94MShares$306 Million0.05% of portfolio
-
Black Rock Inc. New York, NY5.59MShares$288 Million0.0% of portfolio
-
General Atlantic LLC New York, NY5.23MShares$270 Million7.15% of portfolio
About Akero Therapeutics, Inc.
- Ticker AKRO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 46,417,600
- Market Cap $2.39B
- Description
- Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regula...